Logo image
A systematic review and network meta-analysis comparing Rezūm with transurethral needle ablation and microwave thermotherapy for the management of enlarged prostate
Journal article   Open access   Peer reviewed

A systematic review and network meta-analysis comparing Rezūm with transurethral needle ablation and microwave thermotherapy for the management of enlarged prostate

Ansh Bhatia, Joao G. Porto, Renil S. Titus, Vishal Ila, Khushi Shah, Ankur Malpani, Diana M. Lopategui, Robert Marcovich, Thomas R. W. Herrmann and Hemendra N. Shah
BJUI compass
2024-04-29

Abstract

Life Sciences & Biomedicine Science & Technology Urology & Nephrology
ObjectivesWe aim to compare efficacy and safety of water vapour therapy (Rez & umacr;m), transurethral needle ablation (TUNA) and transurethral microwave therapy (TUMT) for treating men with moderate to severe benign prostatic hyperplasia (BPH) symptoms.MaterialsPubMed/MEDLINE, EMBASE and Cochrane Library were searched from inception to 30 July 2023, followed by reference searching and dual-independent study selection. We analysed only randomized clinical trials. RoB-2, NIH-quality assessment tool and GRADE guidelines were used for quality-of-evidence (QoE) assessment. Relevant prospective studies without a critical risk-of-bias were included.ResultsAt 12 months, Rez & umacr;m showed similar efficacy to TUNA and TUMT for improvement in International Prostate Symptoms Score - Rez & umacr;m versus TUMT: 1.33 points (95% CI: -1.66 to 4.35) favouring TUMT (QoE: Moderate) and Rez & umacr;m versus TUNA: 0.07 points (95% CI: -3.64 to 3.88) favouring TUNA (QoE: Low). Rezum had similar outcomes to TUNA and TUMT for Maximum Peak-Flow Rate (Qmax): Rez & umacr;m versus TUMT: 1.05 mL/s (95% CI: -4.88 to 2.82) favouring Rez & umacr;m (QoE: Low) and Rez & umacr;m versus TUNA: 0.37 mL/s (95% CI: -4.61 to 4.21) favouring TUNA (QoE: Low). Furthermore, post-void residual volume (PVR) comparisons demonstrated that Rez & umacr;m was similar, or inferior to other techniques at 12 months - Rez & umacr;m versus TUMT: 11.20 mL (95% CI: -32.40 to 10.30) favouring TUMT (QoE: Low) and Rez & umacr;m versus TUNA: 24.10 mL (95% CI: 2.81 to 45.10) favouring TUNA (QoE: Low). Rez & umacr;m also had a similar surgical retreatment rate with TUMT and TUNA up to 3-years - TUMT versus Rez & umacr;m RR: 1.21 (95% CI: 0.20 to 15.90) (QoE: Low) and TUNA versus Rez & umacr;m showed RR: 1.81 (95% CI: 0.2 to 24.60) (QoE: Low). In the first 12 months after treatment, Rez & umacr;m had a higher rate of serious adverse events (Clavien-Dindo >= Grade 3) than TUMT and TUNA. TUMT versus Rez & umacr;m with RR = 0.53 (95% CI: 0.13 to 3.14) (QoE: Low) and TUNA versus Rez & umacr;m with RR = 0.38 (95% CI: 0.04 to 3.49) (QoE: Low).ConclusionsModerate to weak evidence suggests that Rez & umacr;m is not superior to TUNA and TUMT in all domains studied.
pdf
A systematic review and network meta-analysis comparing Rezūm with transurethral needle ablation and microwave thermotherapy for the management of enlarged prostate1.92 MBDownloadView
Open Access CC BY V4.0
url
https://doi.org/10.1002/bco2.361View
Published (Version of record) Open

Metrics

Details

Logo image